HYPAQUE
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Aug 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
HYPAQUE by GE HealthCare is clinical pharmacology retrograde introduction of hypaque-cysto solution provides radiopacity of the contents of the urinary bladder. First approved in 1969.
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYPAQUE is a water-soluble contrast medium containing diatrizoate meglumine used for retrograde cystourethrography to visualize the urinary bladder and lower urinary tract via fluoroscopy. It provides radiopacity of bladder contents and can detect cystoureteric reflux during micturation as a diagnostic function test. The agent remains localized in the urinary tract with minimal systemic absorption unless pyelorenal intravasation occurs.
LOE Approaching
Product approaching loss of exclusivity with limited linked job activity; team likely focused on lifecycle management and cost containment rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Retrograde introduction of HYPAQUE-CYSTO solution provides radiopacity of the contents of the urinary bladder. When used during micturation as a function test, it also opacifies the bladder neck and lower urinary tract. Continuous fluoroscopic and monitoring of urinary bladder…
Worked on HYPAQUE at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.